What is inflammation of the skin and what does it look like? Inflammation is the skin's response to "irritation, infection or ...

Rosacea treatments include topical creams and light therapy. The goal of treatment is to reduce inflammation. Find OTC and ...

Xyngari™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, Xyngari™ has been studied for ...

Treatment for allergic or irritant contact ... the American Osteopathic College of Dermatology explains that applying the topical product Tecnu within 15 minutes of exposure to poison ivy may ...

The first is the type of treatment you prefer. Some people prefer topical treatments, such as creams or ointments, while others prefer oral medications. The second factor to consider is the ...

Doctors prescribe it for people with moderate to severe atopic dermatitis when topical treatments do not manage the condition well. Tralokinumab-ldrm (Adbry) is another biologic drug the FDA has ...

You've probably heard of a condition called rosacea, but did you know that it can affect the eyes? Rosacea is a condition that commonly affects the nose, face, and chest. Rosacea can be chronic and ...

Medications remain a cornerstone of rosacea treatment, with topical treatments like metronidazole and azelaic acid being commonly prescribed to reduce redness and inflammation. Oral antibiotics ...

A person may be able to treat eczema without steroids. Possible treatment options include topical calcineurin inhibitors, crisaborole, JAK inhibitors, and more. Corticosteroids (steroids ...

TP-04 is an investigational topical sterile ophthalmic gel formulation ... Tarsus is studying TP-04 for the potential treatment of Ocular Rosacea (OR). About TP-05 TP-05 is an investigational ...

TP-04 is an investigational topical sterile ophthalmic gel formulation ... Tarsus is studying TP-04 for the potential treatment of Ocular Rosacea (OR). About TP-05 TP-05 is an investigational ...

Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement.